Pluristem Therapeutics Profit Margin

Pluristem Therapeutics (PSTI) currently reports a profit margin of -2496.95% as of June 2026. That compares with -414.67% in the prior-year period — down 502.2% year over year. That is below the Healthcare sector average of 9.48%. Use the charts on this page to explore Pluristem Therapeutics's profit margin history and peer comparisons.

Pluristem Therapeutics's profit margin decreased from -414.67% to -2496.95% — a 502.2% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Pluristem Therapeutics's profit margin of -2496.95% is lower than the Healthcare sector average of 9.48%. That is roughly 26436.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Pluristem Therapeutics's current -2496.95% should be judged against Healthcare norms (sector average: 9.48%) and against PSTI's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -2496.95%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 9.48%. From there, open related valuation or income-statement pages for Pluristem Therapeutics, and consider following PSTI for alerts when major investors trade the stock.